Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis

July 8, 2011 By Bio-Medicine.Org

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ — Novartis
Pharmaceuticals Corporation (“Novartis”) announced today Phase III
trial results that showed more than one-third of patients taking
Afinitor® (everolimus) tablets* experienced a 50% or greater
reduction in the size of their subependymal giant cell astrocytomas
(SEGAs), non-cancerous brain tumors associated with tuberous
sclerosis complex (TSC)(1,2,6). This study, the largest prospective
clinical trial to date in this patient population, is being
presented on Saturday, July 9 at the International TSC Research
Conference in Washington, D.C.

Currently, Afinitor is approved in the US for the following
indication: to treat patients with SEGA associated with tuberous
sclerosis who require therapeutic intervention but are not
candidates for curative surgical intervention. The effectiveness of
everolimus is based on an analysis of change in SEGA volume.
Additionally, the indication states, clinical benefit such as
improvement in disease-related symptoms or increase in overall
survival has not been shown(7).

Tuberous sclerosis complex affects approximately 25,000 to
40,000 people in the US and one to two million people worldwide,
and is associated with a variety of resulting disorders including
seizures, swelling in the brain (hydrocephalus), developmental
delays and skin lesions(2,6). Also known as tuberous sclerosis
(TS), TSC is a genetic disorder that may cause non-cancerous tumors
to form in vital organs and can affect many different parts of the
body, most commonly the brain and kidney(6,8). Signs and symptoms
of TSC vary depending on which system and which organs are
involved(6). SEGAs occur in up to 20% of patients with TSC. In
countries where everolimus is not approved, brain surgery is the
only treatment option for patients with growing SEGAs(2).

The 117-patient, randomized, placebo-controlled Phase III
EXIST-1 (EXamining everolimus In a Study of TSC) trial met its
primary endpoin

‘/>”/>

SOURCE

Related Articles Read More >

Axoft Fleuron brain-computer interface BCI probe
Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
UC Berkeley and UC San Diego researchers develop way to restore speech using BCIs (1)
Researchers use BCIs to restore speech in people with paralysis
An image of Abbott's Infinity deep brain stimulation (DBS) implants and leads.
As Abbott studies DBS for depression, what might be next?
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe